The 7 analysts offering 12-month price forecasts for Halozyme Therapeutics Inc have a median target of 53.00, with a high estimate of 63.00 and a low estimate of 21.00. The median estimate represents a +22.12% increase from the last price of 43.40.
The current consensus among 8 polled investment analysts is to Buy stock in Halozyme Therapeutics Inc. This rating has held steady since August, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share $0.32
Reporting Date Nov 08
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.